Growth-hormone research · Research peptide analogue
Also known as CJC-1295 DAC, CJC-1295 Drug Affinity Complex, DAC-GRF
A long-acting growth-hormone-releasing-hormone analogue with an albumin-binding Drug Affinity Complex. It is distinct from the non-DAC form.[1]
Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population.
Reviewed Jul 22, 2026 · U.S.-focused reference profile
Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.
Orientation
Start with identity and research context. Similar names do not establish equivalent products or evidence.
Published research or product contexts. These are not personal indications.
Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.
What is known
Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population. This is a description, not a rating or recommendation.
Body-composition and secretagogue research
Small randomized studies in healthy adults found prolonged changes in growth hormone and IGF-I after subcutaneous administration. They measured pharmacodynamic biomarkers, not clinical benefit, and were too small and short to establish treatment safety or effectiveness.
No approved indication, patient-outcome benefit, or adequate long-term safety evidence exists. Findings for the DAC molecule cannot be transferred to the non-DAC form, and product identity in unapproved markets may be unreliable.
Source [2]Rat and laboratory studies examined albumin binding and prolonged hormone-axis stimulation of the DAC molecule. They do not establish clinical outcomes or long-term safety in people.[3]
More human evidence does not automatically transfer to a different product, route, population, or purpose. Limited evidence does not prove no biological activity; it means the relevant clinical question is not established by the reviewed material.
What needs caution
Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.
Reported short-term events included injection-site reactions and headache. FDA also identified unresolved endocrine, impurity, aggregation, immunogenicity, and long-term safety concerns; stimulating the GH/IGF-I axis may have effects not captured in short studies.
Research or cosmetic products may add identity, strength, purity, sterility, contamination, or formulation concerns. This is separate from the evidence about the compound itself.Source [1]No approved indication, patient-outcome benefit, or adequate long-term safety evidence exists. Findings for the DAC molecule cannot be transferred to the non-DAC form, and product identity in unapproved markets may be unreliable.
Human outcomes, long-term safety, formulation identity, and product consistency remain limited or unresolved in the cited material.Source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are different kinds of information. A risk in one product label may not apply to every formulation; an uncertainty proves neither safety nor harm.
Match the product
Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.
The human literature studied a specific DAC-modified molecule. No FDA-approved formulation exists, and marketed products may not match the studied material.
Subcutaneous administration describes the cited early human studies only; it is not an approved route or an instruction for use.
U.S. product context
No FDA-approved medicine was identified for this defined material. Research findings and products sold outside reviewed trials should not be treated as approval.
Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.
CJC-1295 with DAC is not FDA approved. FDA found the evidence insufficient to support inclusion of CJC-1295-related substances on the 503A bulks list.
Specific form or route not separately published in this record.View sourceTake it forward
Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.
Trace the record
Each source supports the section that cites it; publication does not imply endorsement or suitability.
FDA briefing document for CJC-1295-related substances
U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: CJC-1295-related substances. 2024.
U.S. Food and Drug Administration · Published Oct 29, 2024 · Accessed Jul 22, 2026 · Regulatory source
Open sourceHuman pharmacodynamic studies of CJC-1295 with DAC
Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
PubMed-indexed primary study · Published Mar 1, 2006 · Accessed Jul 22, 2026 · Clinical study
Open sourceAlbumin-binding preclinical study of CJC-1295 with DAC
Jette L, et al. Human growth hormone-releasing factor with a prolonged half-life stimulates growth hormone and insulin-like growth factor I secretion in rats. Endocrinology. 2005;146(7):3052-3058.
PubMed-indexed primary study · Published Jul 1, 2005 · Accessed Jul 22, 2026 · Preclinical study
Open sourceIdentity, human evidence, laboratory and animal findings, risks, uncertainty, and U.S. product status are shown separately. Missing information stays marked as unpublished instead of being inferred.
